Oregon
Rule Rule 332-026-0000
Access to and Administration of Legend Drugs and Devices


(1) An LDM is prohibited from purchasing or administering legend drugs and devices, until the continuing education listed in OAR 332-020-0010 (Continuing Education) has been completed and attestation submitted to the Office upon renewal.
(2) Pursuant to ORS 687.493 (Authority to purchase and administer certain legend drugs and devices), an LDM who completes the continuing education listed in OAR 332-020-0010 (Continuing Education) is authorized to purchase and administer legend drugs and devices listed in OAR 332-026-0010 (Approved Legend Drugs For Maternal Use), 332-026-0020 (Approved Legend Drugs For Neonatal Use), and 332-026-0030 (Approved Devices).
(3) An LDM must comply with all local, state and federal laws and regulations regarding the administration, distribution, storage, transportation and disposal of legend drugs and devices listed in OAR 332-026-0010 (Approved Legend Drugs For Maternal Use), 332-026-0020 (Approved Legend Drugs For Neonatal Use), 332-026-0030 (Approved Devices).
(4) Approved legend drugs must be inventoried and securely stored when the product is not in use, including samples or any remaining portion of a drug.
(5) Records regarding approved legend drugs and devices must be maintained for five years. Records must be kept on the business premises and available for inspection upon request by the Office. Upon request by the Board or Office, an LDM must provide a copy of records. Records must include, but are not limited, to the following:
(a) Name of drug, amount received, date of receipt, and drug expiration date;
(b) Name of drug and to whom it was administered; date and amount of drug administered to client;
(c) Name of drug, date and place or means of disposal.
(6) Expired, deteriorated or unused legend drugs must be disposed of in a manner that protects the LDM, client and others who may come into contact with the material during disposal.
(7) An LDM is required to obtain the continuing education for intravenous antibiotics for Group B Streptococcal prophylaxis, however a LDM is not required to administer the antibiotic.
Source
Last accessed
Oct. 21, 2020